Emerging uses of biomarkers in lung cancer management

Molecular mechanisms of resistance

Shirin Attarian, Numa Rahman, Balazs Halmos

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Management of patients with advanced non-small cell lung cancer (NSCLC) has recently been transformed by molecularly targeted and immunotherapeutic agents. In patients with EGFR/ALK/ROS mutated NSCLC, first line molecular therapy is the standard of care. Moreover, immune checkpoint inhibitors are revolutionary treatment options for advanced NSCLC and are now the standard of care in front-line or later line settings. Both classes of agents have led to improved patient outcomes, however, primary resistance and development of acquired resistance to both targeted and immunotherapeutic agents is commonly observed, limiting the use of these agents in clinical settings. In this review, we will discuss the most recent advances in understanding the mechanisms of primary and acquired resistance, progress in the spectrum of assays detecting causative molecular events and the development of new generations of inhibitors to overcome acquired resistance.

Original languageEnglish (US)
Article number377
JournalAnnals of Translational Medicine
Volume5
Issue number18
DOIs
StatePublished - Sep 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Lung Neoplasms
Biomarkers
Standard of Care
Therapeutics

Keywords

  • ALK
  • Epidermal growth factor receptor (EGFR)
  • Immune checkpoint inhibitor
  • MET
  • Molecular mechanisms
  • Resistance
  • ROS
  • T790M
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Emerging uses of biomarkers in lung cancer management : Molecular mechanisms of resistance. / Attarian, Shirin; Rahman, Numa; Halmos, Balazs.

In: Annals of Translational Medicine, Vol. 5, No. 18, 377, 01.09.2017.

Research output: Contribution to journalArticle

@article{9aff054eda0046ad814032fd1cb22104,
title = "Emerging uses of biomarkers in lung cancer management: Molecular mechanisms of resistance",
abstract = "Management of patients with advanced non-small cell lung cancer (NSCLC) has recently been transformed by molecularly targeted and immunotherapeutic agents. In patients with EGFR/ALK/ROS mutated NSCLC, first line molecular therapy is the standard of care. Moreover, immune checkpoint inhibitors are revolutionary treatment options for advanced NSCLC and are now the standard of care in front-line or later line settings. Both classes of agents have led to improved patient outcomes, however, primary resistance and development of acquired resistance to both targeted and immunotherapeutic agents is commonly observed, limiting the use of these agents in clinical settings. In this review, we will discuss the most recent advances in understanding the mechanisms of primary and acquired resistance, progress in the spectrum of assays detecting causative molecular events and the development of new generations of inhibitors to overcome acquired resistance.",
keywords = "ALK, Epidermal growth factor receptor (EGFR), Immune checkpoint inhibitor, MET, Molecular mechanisms, Resistance, ROS, T790M, Targeted therapy",
author = "Shirin Attarian and Numa Rahman and Balazs Halmos",
year = "2017",
month = "9",
day = "1",
doi = "10.21037/atm.2017.07.18",
language = "English (US)",
volume = "5",
journal = "Annals of Translational Medicine",
issn = "2305-5839",
publisher = "AME Publishing Company",
number = "18",

}

TY - JOUR

T1 - Emerging uses of biomarkers in lung cancer management

T2 - Molecular mechanisms of resistance

AU - Attarian, Shirin

AU - Rahman, Numa

AU - Halmos, Balazs

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Management of patients with advanced non-small cell lung cancer (NSCLC) has recently been transformed by molecularly targeted and immunotherapeutic agents. In patients with EGFR/ALK/ROS mutated NSCLC, first line molecular therapy is the standard of care. Moreover, immune checkpoint inhibitors are revolutionary treatment options for advanced NSCLC and are now the standard of care in front-line or later line settings. Both classes of agents have led to improved patient outcomes, however, primary resistance and development of acquired resistance to both targeted and immunotherapeutic agents is commonly observed, limiting the use of these agents in clinical settings. In this review, we will discuss the most recent advances in understanding the mechanisms of primary and acquired resistance, progress in the spectrum of assays detecting causative molecular events and the development of new generations of inhibitors to overcome acquired resistance.

AB - Management of patients with advanced non-small cell lung cancer (NSCLC) has recently been transformed by molecularly targeted and immunotherapeutic agents. In patients with EGFR/ALK/ROS mutated NSCLC, first line molecular therapy is the standard of care. Moreover, immune checkpoint inhibitors are revolutionary treatment options for advanced NSCLC and are now the standard of care in front-line or later line settings. Both classes of agents have led to improved patient outcomes, however, primary resistance and development of acquired resistance to both targeted and immunotherapeutic agents is commonly observed, limiting the use of these agents in clinical settings. In this review, we will discuss the most recent advances in understanding the mechanisms of primary and acquired resistance, progress in the spectrum of assays detecting causative molecular events and the development of new generations of inhibitors to overcome acquired resistance.

KW - ALK

KW - Epidermal growth factor receptor (EGFR)

KW - Immune checkpoint inhibitor

KW - MET

KW - Molecular mechanisms

KW - Resistance

KW - ROS

KW - T790M

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85029676127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029676127&partnerID=8YFLogxK

U2 - 10.21037/atm.2017.07.18

DO - 10.21037/atm.2017.07.18

M3 - Article

VL - 5

JO - Annals of Translational Medicine

JF - Annals of Translational Medicine

SN - 2305-5839

IS - 18

M1 - 377

ER -